Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

9.230 -0.140 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,129,574
Open 9.390
Bid (Size) 9.150 (5)
Ask (Size) 9.440 (2)
Prev. Close 9.370
Today's Range 9.020 - 9.640
52wk Range 4.980 - 43.14
Shares Outstanding 149,483,134
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into BridgeBio Pharma's Return On Capital Employed
 
Via Benzinga
BridgeBio Pharma to Participate in November Investor Events
From BridgeBio Pharma, Inc.
Via Globe NewsWire

Performance

YTD
-46.21%
-46.21%
1 Month
-11.51%
-11.51%
3 Month
-12.10%
-12.10%
6 Month
+40.06%
+40.06%
1 Year
-77.21%
-77.21%

More News

Read More
BridgeBio Pharma: Q3 Earnings Insights
Via Benzinga
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder
Via Benzinga
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
Via Benzinga
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
Via Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
Via Benzinga
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
From BridgeBio Pharma, Inc.
Via Globe NewsWire
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Via Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
From BridgeBio Pharma, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.